LIFE News and Press, aTyr Pharma Inc. From 01/06/22

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has g...

aTyr's lead candidate ATYR1923 recently came out with strong data in a proof of concept trial. Lead indication has a large market in the US. Company is early stage, but looks highly interesting. For further details see: aTyr Pharma: Successful Proof Of Concept In Pulmona...

SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a presentation at the Antibody Engineering & Therapeutics Confere...

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturi...

SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Offi...

aTyr Pharma, Inc. (LIFE) Q3 2021 Earnings Conference Call November 10, 2021 5:00 PM ET Corporate Participants Ashlee Dunston - Director, IR and Corporate Communications Sanjay Shukla - President and Chief Executive Officer Jill Broadfoot - Chief Financial Officer Conference Call Participants ...

aTyr Pharma (NASDAQ:LIFE): Q3 GAAP EPS of -$0.42 beats by $0.15. Cash, cash equivalents and investments as of September 30, 2021 were $116.4 million. Press Release For further details see: aTyr Pharma EPS beats by $0.15

Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initi...

OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...

aTyr Pharma (NASDAQ:LIFE) is scheduled to announce Q3 earnings results on Wednesday, November 10th, after market close. The consensus EPS Estimate is -$0.57 (+16.2% Y/Y) and the consensus Revenue Estimate is $0.27M (+80.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revisio...